• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMJ Open Respiratory Research >Indwelling pleural catheters for non-malignant pleural effusions: report on a single centre’s 10 years of experience
【24h】

Indwelling pleural catheters for non-malignant pleural effusions: report on a single centre’s 10 years of experience

机译：用于非恶性胸膜湿度的留置胸膜导管：报告单一中心的10年经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Recurrent pleural effusion is a common cause of dyspnoea, cough and chest pain during the course of infectious pleurisy and non-malignant diseases like congestive heart failure (CHF) or liver cirrhosis with hepatic hydrothorax (HH). With regard to the chronic character of the underlying diseases, indwelling pleural catheters (IPC) are increasingly used, not only assuring immediate symptom relief but also potentially leading to pleurodesis without sclerosing agents.Patients and methods In this single-centre retrospective observational study, patient characteristics, procedural variables and outcome in patients with IPC in non-malignant pleural effusion (NMPE) were evaluated and prognostic factors for pleurodesis were identified.Results From 2006 to 2017, 54 patients received 62 IPC, of whom 48.4% with CHF and 43.5% with HH. The median length of insertion was 1.5 months (IQR 0.6–2.9 months), the median survival time after insertion 3.2 months (IQR 1.1–16.0). An adequate symptom relief was achieved in 93.2% with no need for subsequent interventions. In patients surviving ≥30 days after IPC insertion, pleurodesis was observed in 45.9%, being associated to age (55 years, p=0.02), the primary diagnosis (p=0.03) and interventions for the underlying disease (p0.001). Complications occurred in 24.2% of all procedures (n=15), the majority concerning mechanical obstructions (n=10) and infections (n=4). Patients with HH had an excess risk for complications (37.3%).Conclusion Efficacy in symptom relief and a generally manageable safety profile recommend IPC as a first-line treatment option in NMPE, where disease-specific treatments are exhausted. Caution is warranted in patients with HH due to an excess risk for complications.
机译：背景技术复发性胸腔积液是呼吸困难，咳嗽和胸部疼痛的常见原因，在传染性胸膜炎和非恶性疾病等中具有充血性心力衰竭（CHF）或肝肝硬化，肝脏氢茶（HH）。关于潜在疾病的慢性特性，越来越多地使用留置胸膜导管（IPC），不仅保证了直接症状浮雕，而且可能导致胸膜瘤病毒，而不导致这种单一中心回顾性观察研究中的患者和方法，患者对非恶性胸腔积液（NMPE）的IPC患者的特征，程序变量和结果被评估，鉴定了胸膜炎的预后因素。从2006年到2017年，54名患者接受了62名IPC，其中CHF和43.5％的48.4％ hh。中位数的插入长度为1.5个月（IQR 0.6-2.9个月），插入后的中位存活时间3.2个月（IQR 1.1-16.0）。 93.2％的症状浮雕达到了93.2％，无需随后的干预措施。在IPC插入后存活≥30天的患者中，观察到45.9％的胸膜瘤，与年龄（<55岁，P = 0.02）相关，主要诊断（P = 0.03）和潜在疾病的干预措施（P <0.001） 。所有程序中的24.2％（n = 15）的并发症发生并发症，大多数关于机械障碍物（n = 10）和感染（n = 4）。 HH患者的并发症风险过多（37.3％）。结论症状浮雕的疗效和一般可控的安全性型材建议IPC作为NMPE中的一线治疗选项，其中疾病特异性治疗耗尽。由于并发症的风险过剩，HH的患者有必要谨慎。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号